Emmanuel Nwangele
Quebec, QC G1V0A6, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 23, 2026
Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple negative breast cancer models.
Journal: International journal of pharmaceutics
Published: December 30, 2025
Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models.
Journal: International journal of pharmaceutics
Published: December 30, 2025
[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.
Journal: Breast cancer research : BCR
Published: August 30, 2025
Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks.
Journal: EJNMMI radiopharmacy and chemistry
Published: June 11, 2025
Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.
Journal: British journal of cancer
Published: December 20, 2024
Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 27, 2024
225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 09, 2024
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.
Journal: Cancer research
Published: July 08, 2024
Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 07, 2024
Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: August 08, 2023
Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics.
Journal: British journal of cancer
Published: October 20, 2022
Showing 1-12 of 12
Last Updated: 09/26/2026